Clinical endpoint

Jazz Pharmaceuticals' Epidiolex Misses Primary Endpoint in Japan Epilepsy Trial: What It Means for Investors

Jazz Pharmaceuticals, a global biopharmaceutical company, recently announced top-line results from a Phase 3 trial in Japan evaluating cannabidiol oral...